#biopharmaceuticals

[ follow ]
#insider-buying #nafta #intellectual-property #economic-growth #trade-agreements #abbvie #jpmorgan #stock-analysis
Business
from24/7 Wall St.
1 week ago

AbbVie Gets JPMorgan Buying Opportunity Call With $260 Price Target Amid Competitive Concerns

JPMorgan maintains an Overweight rating on AbbVie, viewing recent stock pullback as a buying opportunity with a $260 price target.
Healthcare
fromMedCity News
1 week ago

The Drug Companies Avoiding Trump's Tariffs - For Now - MedCity News

President Trump is imposing new tariffs on branded pharmaceuticals while exempting generic medications and certain specialty drugs.
from24/7 Wall St.
3 weeks ago

This 6.5%Yielding Dividend Payer is Sitting on a Breakthrough Investors Haven't Priced In

Pfizer offers a 6.5% dividend yield, which is attractive for investors willing to wait for the company's promising innovations to materialize, despite facing significant challenges.
Venture
#insider-buying
more#insider-buying
fromLondon Business News | Londonlovesbusiness.com
9 months ago

Reeves hit with another blow as AstraZeneca considering leaving the UK

Sir Pascal Soriot has repeatedly highlighted the need for Europe to enhance its incentives for new medicines, warning that jobs could relocate to the US if these conditions remain unchanged.
UK news
from24/7 Wall St.
9 months ago

This Once Dominant Dividend Stock May Be About to Come Back to Life in July

Bristol-Myers Squibb, down over 42% from its peak, is becoming an attractive buy due to its high dividend yield and potential for turnaround.
Startup companies
Digital life
fromComputerWeekly.com
1 year ago

Interview: Markus Schummelfeder, CIO, Boehringer Ingelheim | Computer Weekly

Markus Schümmelfeder's vision as CIO has transformed Boehringer Ingelheim into a data-enabled organisation, emphasizing technology's role in business processes.
[ Load more ]